Physician profile
Dixie D Richards
NPI 1740358464
$1,881.93
in general payments reported to CMS, 2019-2025
11 companies · $298 in 2025
The $298 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.49 · 2020: $235 · 2021: $388 · 2022: $422 · 2023: $150 · 2024: $311 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $758.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $573.76 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $380.46 | 2020-2025 | |
| Allergan, INC. | $270.20 | 2019-2022 | |
| Galderma Laboratories, L.P. | $266.93 | 2020-2021 | |
| Incyte Corporation | $143.37 | 2022 | |
| Amgen INC. | $98.91 | 2022-2025 | Otezla |
| Pfizer INC. | $37.89 | 2019-2022 | |
| Ucb, INC. | $34.75 | 2021-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $28.70 | 2019-2020 | |
| Botanix Sb INC | $26.31 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $20.65 | 2024 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dixie Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.